Search results
We are passionate about patients and science. Join Us. We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs.
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
We have a diverse pipeline designed to make a meaningful difference for patients. Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon ® technologies and our aim to improve patients' lives. We have multiple prodrug therapies in development.
Investors & News. Ascendis Pharma is applying our innovative TransCon™ technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.
Feb 16, 2023 · For the full year 2022, Ascendis Pharma reported a net loss of €583.2 million, or €10.40 per share (basic and diluted) compared to a net loss of €383.6 million, or €7.00 per share (basic and diluted) for the same period in 2021.
Dec 31, 2021 · Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update. - Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter. - Demand for SKYTROFA® (lonapegsomatropin-tcgd), the ...
May 13, 2024 · We are passionate about patients and science. Join Us. We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs.
Ascendis Pharma is applying our innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’...
May 14, 2024 · The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday.
Find the latest Ascendis Pharma A/S (ASND) stock quote, history, news and other vital information to help you with your stock trading and investing.
